Objective: To compare the effects of atorvastatin, fluvastatin, pravastatin, and simvastatin on endothelial function, aortic atherosclerosis, and the content of malondialdehyde (MDA) in native and oxidized LDL and in the arterial wall of hypercholesterolemic rabbits after adjusting the dosages of those statins to reduce total serum cholesterol levels to similar values. Methods: Male rabbits were divided into the following 6 groups of 10 animals (n=10): 1) GH (control) - hypercholesterolemic animals; 2) GA - atorvastatin; 3) GF - fluvastatin; 4) GP - pravastatin; 5) GS - simvastatin; and 6) GN - normal. The animals were fed a standard food preparation enriched with 0.5% cholesterol and 2% coconut oil for 45 days. Fifteen days after beginning the experiment, atorvastatin, fluvastatin, pravastatin and simvastatin were administered for 15 days through gavage, and the dosages were adjusted to obtain similar cholesterol values in each group. At the end of the experiment, a blood sample was withdrawn for determining total cholesterol and separating the lipoproteins, and a segment of the thoracic aorta was removed to be used for studying endothelial function and lipid peroxidation, and for measuring aortic atherosclerosis in histological sections. Results: The statins significantly reduced total serum cholesterol levels, LDL-cholesterol levels, and aortic atherosclerosis. The MDA content was also significantly reduced in native and oxidized LDL, as well as in the arterial wall. Endothelium-dependent relaxation was significantly greater in the treated group compared with that in the hypercholesterolemic group. Conclusion: The statins, at dosages adjusted, had a significant and similar effect in reducing lipid peroxidation in native and oxidized LDL-C and in arterial walls, in decreasing aortic atherosclerosis, and in reverting endothelial dysfunction.844314319Shepherd, J., Cobbe, S.M., Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West Scotland Coronary Prevention Study (WOSCOPS) (1995) N Engl J Med, 333, pp. 1301-1307Domws, J.R., Clearfield, M., Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels (1998) N Engl J Med, 339, pp. 1349-1357(1998) N Engl J Med, 339, pp. 1349-1357Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease (1994) Lancet, 344, pp. 1383-1389Sacks, F.M., Pfeffer, M.A., The effect of pravastatin on coronary events after myocardial infaction in patients with average cholesterol levels. Care Study (1966) N Engl J Med, 14, pp. 1001-1009MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high risk individuals: A randomized placebo-controlled trial (2002) Lancet, 360, pp. 23-33Vaughan, C.J., Gotto, A.M., Basson, C.T., The envolving role of statins in the management of atherosclerosis (2000) J Am Coll Cardiol, 35, pp. 1-10Ricker, P.M., Rifail, N., Lowenthal, S.P., Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hyperchoelsterolemia (2001) Circulation, 103, pp. 1191-1193Bellosta, S., Bernini, F., Ferri, N., Quarato, P., Canavesi, M., Arnaboldi, L., Direct vascular effects of HMGCoA reductase inhibitors (1998) Atherosclerosis, 137, pp. S101-S109Scalia, R., Appel, J.Z., Lefer, A.M., Leukocyte-endothelium interaction during the early stages of hypercholesterolemia in the rabbit (1998) Arterioscl Thromb Vasc Biol, 18, pp. 1093-1100Dangas, G.J., Badimon, L., Smith, D.A., Levine, A., Ambrose, J.A., Pravastatin therapy in hyperlipidemia. Effects on thrombus formation and the systemic hemostatic profile (1999) Am Coll Cardiol, 33, pp. 1294-1304Lefer, A.M., Scalia, R., Lefer, D.J., Vascular effects of HMG-COA reductase inhibitors unrelated to cholesterol lowering: New concepts for cardiovascular disease (2001) Cardiovasc Res, 49, pp. 281-287Williams, D., Feely, J., Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors (2002) Clin Pharmacokinet, 41, pp. 343-370Corsini, A., Maggi, F., Catapano, A.L., Pharmacology of competitive inhibitors of HMGCoA reductase (1995) Pharmacological Res, 31, pp. 9-27Dansette, P.M., Joen, M., Rons, C., HMGCoA reductase activity in human liver microssomes: Comparative inhibition by statins (2000) Exp Tox Pathol, 52, pp. 145-148Jones, P., Kafonek, S., Laurora, I., Hunninghake, Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia. (The Curves Study) (1998) Am J Cardiol, 81, pp. 582-587Ribeiro, J.P.A., Ozaki, M.K., Effects of simvastatin and pravastatin on endothelium-dependent relaxation in hypercholesterolemic rabbits (1994) Exp Toxic Pathol, 46, pp. 465-469Ribeiro, J.P.A., Eros, A.A., Ozaki, M.R., Rapid reversal of endothelial dysfunction in hypercholeterolemic rabbits treated with sinvastatin and pravastatin (1997) Clin Exp Pharmacol Physiol, 24, pp. 948-995Cassini, A.F., Ferrali, M., Pompella, A., Maellaro, E., Comporti, M., Lipid peroxidation and cellular damage in extrahepatic tissue of bromobenzene-intoxicated mice (1986) Am J Pathol, 123, pp. 520-531Havel, R.J., Eder, H.A., Bragdon, J.H., The distribution and chemical composition of ultracentrifugally separated lipoproteins in human serum (1955) J Clin Invest, 34, pp. 1345-1353Lowry, O.H., Rosebrough, N.J., Farr, A.L., Randall, R.L., Protein measurement with the Folin phenol reagent (1951) J Biol Chem, 193, pp. 265-275Parthasarathy, S., Khoo, J.C., Miller, E., Barnett, J., Witztum, J., Steinberg, D.E., Low density lipoprotein rich in oleic acid is preotected against oxidative modifications: Implications for dietary prevention of atherosclerosis (1990) Porc Natl Acad Sci USA, 87, pp. 3894-3898Buege, J.A., Aust, S.D., Microsomal lipid peroxidation (1978) Methods Enzymol, 52, pp. 302-310Lehr, H.A., Mankoff, D.A., Corwin, D., Application of Photoshop-based analysis to quantification of hormone receptor expression in breast cancer (1997) J Histochem Cytochem, 45, pp. 1559-1565Lehr, H.A., Van Der Loos, C.M., Teeling, P., Complete chromogen separation and analysis in double immunohistochemical stains using Photoshop-based image analysis (1999) J Histochem Cytochem, 47, pp. 119-126Fleiss, J.L., (1981) Statistical Methods for Rates and Proportions, , New York: John Wiley, 2nd edMilliken, G.A., Johnson, D.E., (1984) Analysis of Messy Data. Vol I: Designed Experiments, 1. , New York: Van Nostrand ReinholdMotti, C., Gnasso, A., Cortese, C., Statins: Similarities and differences in the pharmacological, clinical and laboratory aspects (2000) Ann Ital Med Int, 15, pp. 96-102Corsini, A., Maggi, F.M., Catapano, A.L., Pharmacology of competitive inhibitors of HMG-CoA reductase (1995) Pharmacol Res, 31, pp. 9-27Negre-Aminou, P., Van Erck, M., Van Leeuwen, R.E., Collard, J.G., Cohen, L.H., Differencial effect of simvastatin on various signal transduction intermediates in cultured human smooth muscle cells (2002) Biochm Pharmacol, 61, pp. 991-998Davignon, J., Mabile, L., Mechanisms of action of statins and their pleiotropic effects (2001) Ann Endocrinol, 62, pp. 101-102. , ParisKoh, K.K., Effects of statins on vascular wall: Vasomotor function, inflammation and plaque stability (2000) Cardiovasc Res, 47, pp. 648-657Takemoto, M., Lia, J.K., Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors (2001) Arterioscler Thrombo Vasc Biol, 21, pp. 1712-1719Hughes, A.D., The role of isoprenoids in vascular smooth muscle: Potential benefits of statins unrelated to cholesterol lowering (1996) J Hum Hypertens, 10, pp. 387-390Carneado, J., Alvarez De Sotomayor, M., Perez-Guerrero, C., Simvastatin improves endothelial function in spontaneiusly hypertensive rats through a superoxide dismutase mediated antioxidant effect (2002) J Hypertens, 20, pp. 429-437Suzumura, K., Tanaka, K., Yasuhara, M., Narita, H., Inhibitory effects of fluvastastin and its metabolites on hydrogen peroxide induced oxidative destruction of hemin and low desnsity lipoprotein (2000) Biol Pharmacol Bull, 23, pp. 837-878Salonen, R., Nyyssonen, K., Porkkala-Sarataho, The Kuopio Atherosclerosis Prevention Study: Effects of pravastatin teatment on lipids, oxidation resistance of lipoproteins and atherosclerosis progression (1995) Am J Cardiol, 76, p. 3Wassmann, S., Laufs, U., Muller, K., Cellular antioxidant effects of atorvastatin in vitro and in vivo (2002) Arterioscler Thromb Vasc Biol, 22, pp. 300-305Laufs, V., Fata Vita, B.A., Plutzky, J., Liao, K., Up regulation of endothelial nitric oxide after lipid lowering therapy in hypercholesterolemic patients (1998) Circulation, 98, pp. 211-216Pentikainen, P.J., Saraheimo, M., Swartz, J.I., Comparative pharmacokinetics of lovastatin, simvastatin and pravastatin in humans (1992) L Clin Pharmacol, 32, pp. 136-140Germershausern, J.I., Hunt, V.M., Bostedor, R.G., Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo (1989) Biochem Biophys Res Comm, 158, pp. 667-675Endo, A., Tsujita, Y., Kuroda, M., Tanzaka, K., Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals (1979) Biochem Biophys Acta, 576, pp. 266-276Thiery, J., Nebendhal, K., Walli, A.K., Effects of three different HMGCoA reductase inhibitors on hypercholesterolemia and atherosclerosis in cholesterol fed-rabbits (1991) Arterioscler Tromb, 11, p. 148DeVries, A.C., Vermeer, M.A., Bloemendal, H., Coehn, L.H., Pravastatin and simvastatin differently inhibit cholesterol biossynthesis humanas lens (1993) Invest Ophthalmol Vis Sci, 34, pp. 377-384Tesfamariam, B., Frohlich, B.H., Gregg, R.E., Differencial effects of pravastatin, simvastatin, and atorvastatin on Ca++ release and vascular reactivity (1999) J Cardiovasc Pharmacol, 34, pp. 95-101Joukhadar, C., Klein, N., Schrolnberger, C., Vukovich, T., Wolzt, M., Dorner, G.T., Similar effects of atorvastatin, simvastatin, simvastatin and pravastatin on thrombogenic and inflammatory parameters in patients with hypercholesterolemia (2001) Thromb Haemost, 85, pp. 47-51Armstrong, M.L., Regression of coronary atheromatosis in rhesus monkeys (1975) Circ Res, 36, p. 256Vesselinovith, D., Reversal of advanced atherosclerosis in reshus monkeys. Light microscopic studies (1976) Atherosclerosis, 23, p. 155David, A.S., Regression of advanced atherosclerosis in swine (1976) Arch Pathol Lab Med, 100, p. 372Helf, G., Worthley, S.G., Fuster, V., Fayad, Z.A., Zaman, A.G., Corti, R., Fallon, J.T., Badimon, J.J., Progression and regression of atherosclerotic lesions: Monitoring with serial noninvasive magnetic resonance imaging (2002) Circulation, 105, pp. 993-998Moreno, P.R., Lodder, R.A., Purusshothaman, K.R., Charash, W.E., Oconnor, W.N., Muller, J.E., Detection of lipid pool,thin fibrous cap,and inflamatory cells in human aortic atherosclerotic plaque by near-infrared spectroscpiy (2002) Circulation, 105, pp. 923-927Van De Pooll, S.W., Delsin, D.J., Jukema, J.W., Raman spectroscopic investigation of atorvastatin, amlodipine, on atherosclerotic plaque development in ApoE3 Leiden transgenic mice (2000) Atherosclerosis, 164, pp. 65-71Nissen, S.E., Tuzcu, E.M., Soenhagen, P., Effects of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial (2004) JAMA, 291, pp. 1071-1080Cannon, P.C., Braunwald, E., McCabe, C.H., Comparison of intensive and moderate lipid lowering with statins after acute coronary syndroms (2004) N Engl J Med, 350, p. 15Mitoni, H., Egashira, K., Kimura, M., Fluvastatin has cholesterol-lowering independent "direct effects" on atherosclerotic vessels in high cholesterol diet-fed rabbits (2003) Pharmacol Res, 48, pp. 417-427Jorge, P.A.R., Endotélio, lípides e aterosclerose (1997) Arq Bras Cardiol, 68, pp. 129-134